Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCHID
2023-507987-38-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic asthma (EA) comparing Benralizumab arm with Placebo arm (2 arms). Primary endpoints: Change from baseline in endoscopic total nasal polyp score (NPS) and Change from baseline in mean nasal blockage score (NBS). Started Feb 2024; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2023-507987-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507987-38-00.